Positive results for ROS1 on Crizotinib

Objective responses occurred in 72% of patients. 50 patients on trial. The PFS WAS 19.2 months. REMARKABLE!

Here is an article in the NEJM.

http://www.nejm.org/doi/full/10.1056/NEJMoa1406766?query=featured_home

Other articles:

http://www.bloomberg.com/news/2014-09-27/pfizer-s-lung-cancer-drug-helps-patients-with-gene-defect.html

http://www.medpagetoday.com/MeetingCoverage/ESMO/47854

Look at the attached comment also.

This entry was posted in crizotinib - Xalkori from Pfizer. Bookmark the permalink.

One Response to Positive results for ROS1 on Crizotinib

Leave a Reply